Caliway Biopharmaceuticals Co. L
6919
Rang in aandelen
#4346
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aandeelprijs
$2.29
Marktkapitalisatie
$3.56B
Verandering (1 dag)
-2.50%
Verandering (1 jaar)
-57.22%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Categorie
Healthcare
EPS voor Caliway Biopharmaceuticals Co. L (6919)
EPS per 2026 TTM: 0
Volgens de laatste financiële rapporten en de aandelenkoers van Caliway Biopharmaceuticals Co. L is de huidige EPS van het bedrijf (TTM) 0. Eind 2026 had het bedrijf een EPS van 0, gelijk aan de EPS van 2026 die 0 bedroeg.
EPS-geschiedenis van Caliway Biopharmaceuticals Co. L van 2019 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2025 | $-0.01 | -41.60% |
| 2024 | $-0.01 | -1.57% |
| 2023 | $-0.01 | 62.82% |
| 2022 | $-0.01 | -10.34% |
| 2021 | $-0.01 | 89.13% |
| 2020 | 0.00 | -19.30% |
| 2019 | $-0.01 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
